Sionna Therapeutics, Inc. Common Stock SION Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $18.96M+38.7% | $15.17M+6.4% | $16.04M-34.7% | $15.38M+86.8% | $13.67M+33.7% | ||
| $10.64M+77.5% | $8.44M+118% | $7.76M+128% | $6.52M+113% | $5.99M+105% | ||
| $29.6M+50.6% | $23.61M+30.2% | $23.81M-14.9% | $21.91M+94.0% | $19.66M+49.5% | ||
| -$29.6M-50.6% | -$23.61M-30.2% | -$23.81M+14.9% | -$21.91M-94.0% | -$19.66M-49.5% | ||
| $2.82M-11.2% | $3.17M+38.8% | $3.53M+38.7% | $3.84M+40.1% | $3.18M+144% | ||
| -$26.78M-62.5% | -$20.44M-29.0% | -$20.28M+20.3% | -$18.07M-111% | -$16.48M-39.1% | ||
| -$0.60+3.2% | -$0.45+85.8% | -$0.46+91.9% | -$410.00+84.9% | -$0.62+100.0% | ||
| -$29.45M-51.0% | -$23.46M-30.6% | -$23.71M+14.7% | -$21.81M-96.6% | -$19.5M-50.2% | ||
| -$29.6M-50.6% | -$23.61M-30.2% | -$23.81M+14.9% | -$21.91M-94.0% | -$19.66M-49.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Sionna Therapeutics, Inc. Common Stock profitable?
- Sionna Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $85.6M over the trailing twelve months.
- What is Sionna Therapeutics, Inc. Common Stock's earnings per share?
- Sionna Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-411.51.
- Where does Sionna Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Sionna Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.